secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2023-05-08T23:59:59+00:00
Accession:  0001069530-23-000021
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cassava Sciences shareholder vote fails to approve officer liability limitation
-------------------------------------------------------------------------------

- Directors Robert Z. Gussin (7.1M for) and Richard J. Barry (6.7M for) elected to three-year terms.
- Proposal to limit officer liability failed; received 87% of votes cast but not a majority of outstanding shares (7.8M for vs 24.8M outstanding).
- Non-employee director compensation program approved with 7.8M for, 986K against.
- Ernst & Young ratified as auditor for FY2023 with 24.1M for, 532K against.
- Advisory say-on-pay approved (6.6M for, 2.1M against); frequency set to every one year (8.2M votes).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000106953023000021/0001069530-23-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000106953023000021/sava-20230504x8k.htm
  HTML page:      https://secwatch.observer/filing/0001069530-23-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer